From Promise to Progress: More Durable Treatments for Neovascular Retinal Diseases - nAMD Interactive Data Deep Dive

Program Overview:,This engaging infographic activity will take learners on an interactive, multimedia journey through the pivotal phase 3 trials that led to the recent FDA approvals of 2 exciting new therapies for the treatment of neovascular retinal diseases—faricimab, a first-in-class bispecific antibody indicated for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), and the ranibizumab port delivery system (PDS), a first-of-its-kind sustained anti-vascular endothelial growth factor delivery device indicated for nAMD.,Learning Objectives:,Upon completion of this activity, participants should be able to:,• Articulate clinical trial designs of recently available novel therapies that are indicated for the treatment of neovascular retinal diseases,• Summarize safety and efficacy data for recently available novel treatments for neovascular retinal diseases.